Introduction
Multiple sclerosis (MS) is considered as an autoimmune, chronic and inflammatory condition that leads to degeneration of neurons and abnormal immune responses occurred in the central nervous system (CNS). The disease is regarded as the most common non-traumatic cause of CNS injury in young and adult subjects. The immune system has critical role in the pathogenesis of MS [1] [2] [3] [4] . During most of the MS cases, the disease form is relapsingremitting (RRMS) in initial disease course with periods of relapse, which is then followed by periods of remission [5] . Over the course of last decades, huge progress has been made in the therapy of MS. After several decades of treatment with disease-modifying treatments (DMTs), including interferon (IFN)-β and glatiramer acetate. Currently, effective therapies for MS are available. The first oral DMT was fingolimod, which was approved in 2010 in the United States. Afterwards, several other oral drugs have been approved or are in the process of phase III clinical trials [6] . To date, three monoclonal antibodies have been approved for treatment of MS and some other antibodies in the final state of developing.
Despite a promising advancement in therapeutic approaches of MS, the current approaches could not meet the future needs because of the complicated etiopathogenesis of the disease. In this review, we have discussed the monoclonal antibodies developed for therapy of MS.
Etiology of MS
MS is a multifactorial disease the exact causes of which are unknown; scientists believe that MS is probably due to a change in the immune system or contact with environmental factors (infectious agents) or both. The immune system plays an important role in creating MS disease in which macrophages, killer T cells, lymphokines and antibodies attack their own myelin or oligo-dendritic antigens in case of penetration into the brain [7] .
The MS susceptibility is associated with a very [12] . The electron transfer chain is impeded by NO, thereby elevating H2O2 production, activating NF-κB and expressing iNOS and cyclooxygenase 2 [13] . The macrophage/microglia can also be activated by NO, and H2O2 and NO can in turn be released increasingly from these cells [14] .
Mitochondrial dysfunction, inflammationdriven oxidative stress, and the presence of divalent metal ions (which catalyse the generation of highly toxic OH-radicals from H2O2) all result in generation of oxygen free radicals [15] . Free radicals interfere with de novo synthesis of respiratory chain components and can directly induce mitochondrial DNA damage [16] . The expression of enzymes involved in free radical production markedly increases in active MS lesions, most prominently in areas of initial tissue injury [17] .
Oxidized DNA and lipids, as well as nitrotyrosine, a marker of peroxynitrite-induced tissue injury, are all abundantly present in active MS lesions [18] .
A study found the nitrotyrosine accumulation in oligodendrocyte in a young patient suffering from early MS, which then contributed to ONOO¯ mediated damage [17] . The ONOO¯ is unable to induce the oligodendrocyte apoptosis;
and necrosis has been reported as the active cause of the cell death [19] . It should be noted that the astrocytes show intermediate resistance to ONOO¯. The ONOO¯ may indirectly stimulate the key pathophysiological consequences of high level of NO. DNA singlestrand is cleaved by peroxynitrite that then activates poly (ADP-ribose) polymerase (PARP) [13] .
The apoptosis-inducing factor is released due to the damaged mitochondria in oligodendrocytes, followed by translocation into the nucleus to activate PARP that is an in vivo mechanism proven in the cuprizone intoxication-induced model of oligo dendrocyte destruction and demyelination [20] . Age in human leads to the accumulation of iron in the brain, mostly in oligodendrocytes. It is detoxified through binding to ferritin and increases during young adulthood with a plateau of 40 to 50 years of age which shows elevated cerebral iron loading [21] . The MS pathogenesis is strongly associated with the activation of PARP [20] . Further MS processes can be organized due to astrocytederived NO. The iNOS overexpression in macrophages early during the disease and before demyelization has also been reported [26] . Moreover, the arginine injection (acting as either iNOS substrate or up-regulator of iNOS mRNA) [27] into the rat brain induces demyelination, indicating the role of iNOS expression in developing MS [14] . The oligodendrocyte death is triggered by the NO, HNE and H2O2 leaked from astrocytes and macrophages. In additin, the mice with eNOSdeficient experience a delayed experimental autoimmune encephalomyelitis (EAE) initiation, which indicates the importance of eNOS in the onset of MS; it relates with delayed blood-brain barrier (BBB) breakdown [28] .
Pathophysiology
The most frequent cells found in the human brain are the astrocytes that establish an optimal physical and metabolic environment for neuronal activities and play an important role in the neuronal redox homeostasis, potassium balance, BBB regulation, myelination, neurotransmitter uptake, and synapse formation and function. Electrical signaling in the neurons is responsible for transmitting information. The myelination of long processes in axons and neurites is necessary to efficiently conduct signals. Among these, the oligodendrocytes support and insulate the axons through myelin sheath formation [29] .
Myelin is a protective coating that is made of fat and protein and helps the nerve fiber forward the message. In MS disease, plaques Dystrophic or demyelinated axons have shown aberrant expression of Na + channels, acidsensing Na + channels, glutamate receptors [31] , and voltage-gated Ca 2+ channels. Intra-axonal Ca 2+ accumulation and axonal degeneration simultaneously directly or indirectly have been found following the changes in the expression and activity of these ion channels.
Immunopathogenesis of MS
The genetic and environmental factors obviously affect the MS as an immunepathologic disease (probably an autoimmune disease). BBB consisting endothelial cells create strong interconnections-tight junctions [32] . BBB formation and function require essentially the astrocytes and pericytes [33] . [36] . Activated demyelination and neurodegeneration are invariably related to inflammation in primary progressive MS (PPMS) and SPMS [37] . The inflammatory process in the brains of PPMS or SPMS patients is also dissociated from BBB damage, resulting in inflammatory infiltration encountered around small veins and venules without evidence of loss of BBB integrity [38] .
The cortical demyelination has been shown to be significantly and strongly associated with diffuse meningeal inflammation. A majority of lesions contain CD3 + cells (as a key immunohistochemical marker for T cells in general) and CD8 + T cells, but not the CD4 + T ones [39] . In a study, CCR6 + T cells were found in early cortical lesions indicating that T cells infiltrate CSF using choroid plexus/CCL20 route and proceed to the cortex by provoking IL-17-dependent redistribution of CCL20 on the walls of blood vessels [40] . [66] .
Secukinumab (AIN457)
Secukinumab is a human monoclonal antibody IgG1κ. The mechanism of action of this drug is through the inhibition of proinflammatory cytokine IL-17A [67] , that are produced by Th17 cells, as well as by macrophages, neutrophils, natural killer cells, dendritic cells, mast cells, and γδ-T cells.
MOR103
MOR103 is a human monoclonal antibody IgG1. The mechanism of action of this drug is through interfering the interaction between granulocyte-macrophage colony-stimulating factor (GM-CSF) and its receptor that in turn leads to turning off its signaling pathway [68] .
Macrophages and dendritic cells activation, maturation and differentiation are provoked by GM-CSF, so it is a pro-inflammatory factor in cell-mediated immune responses [69] .
GNbAC1
GNbAC1 is a recombinant DNA-derived humanized monoclonal antibody (IgG4/κ isotype) that contains framework regions and complementarity-determining regions from human and parent murine antibodies, respectively. The mechanism of action of this antibody is through direct binding to extracellular domain of MS-associated retrovirus envelope protein (MSRV-Env) [70] . No physiological role is known for the MSRV-Env protein, but it is over-expressed in brain of MS patients [71] . As it is mentioned, proinflammatory agents are involved in the pathogenesis of MS. MSRV-Env Protein plays a pro-inflammatory role by interacting with tolllike receptor 4.
Ustekinumab
Ustekinumab is a human monoclonal antibody and IFNγ, IL17 and IL-17-producing Th17 CD4 + cells, respectively [73] .
Lovett-Racke et al. demonstrated significant relation between dysregulation of the Th1/Th17
pathways and MS disease [74] . These results created ideas for the use of drugs against these cytokines. In line with these results, some research confirmed that administration of IL-12 leads to an increase in EAE in rodents and marmosets [75] . They also showed that anti-IL-12 antibodies result in decreasing the EAE.
C. Monoclonal antibodies targeting B cells
The role of B cells has long been debatable in MS pathogenesis; there are some signs (B cells existence, plasma blasts and immunoglobulin in MS lesions, and also immunoglobulin and oligoclonal connections in CNS that B cells are involved in MS disease pathogenesis [76] . It seems that B cells play some role in T cells activation, cytokines production, demyelination, and re-myelination [77] . Therefore, it seems reasonable that there are antibodies that target CD20 in the surface of B cells. Wootla et al. have proven that B cells play a significant role in the initiation and propagation of MS [78] .
Therefore, targeting CD20 [79] or CD19 [80] by monoclonal antibody can help improve MS disease.
Rituximab
Rituximab is the first anti-CD20 monoclonal antibody. Rituximab is a chimeric monoclonal antibody IgG1 that targets CD20 in the surface of B cells line; the effect of this drug is applied by antibody dependent cell cytotoxicity and complement dependent cytotoxicity apoptosis.
This monoclonal antibody has been designed for B cells lymphoma treatment at first [81] .
Ocrelizumab
Ocrelizumab like rituximab targets the CD20 containing cells line with the exception of plasma cells. Both mentioned monoclonal antibodies induce apoptosis and reduce B lymphocytes. Ocrelizumab is a humanized monoclonal antibody IgG1, unlike rituximab; therefore, it seems that ocrelizumab may have less allergic reactions and also less anti-idiotype antibodies. Contrary to rituximab, its efficiency is more likely revealed by antibody dependent cell cytotoxicity and complement dependent cytotoxicity [82] .
Ofatumumab (Arzerra)
Ofatumumab is a fully human monoclonal antibody IgG1 that targets CD20 in the surface of B cell line. The mechanism of the action of Ofatumumab is different from the two previous ones. This antibody inhibits B cell activation by attaching to a different position of the CD20 receptor.
Initially, this antibody was made by transgenic mice; however, by using genetic engineering techniques, human's heavy and light chains genes are transfected to mouse myeloma cell line. It seems that its decreasing effect on B cell by complement dependent cytotoxicity is more than rituximab.
Tabalumab
Tabalumab is a human monoclonal antibody.
The mechanism of action of this antibody is not exerted by binding to CD19 and 20, but it binds to BAFF and CD257 [83] and suppresses the activation of the B cells. BAFF is a member of TNF super family which, by binding to the receptor on the mature B cells, has a key role in survival and maturation of B cells [84] . 
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